Polycystic Ovary Syndrome
Conditions
Interventions
Control group:Oral administration of metformin
group A:Tirzepatide injection therapy
group B:Treatment with metformin combined with tirzepatide
Sponsors
The Second Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Women of childbearing age aged 18 - 40 years; 2. BMI ranging from 24.0 to 38.0 kg/m^2; 3. Without other serious chronic diseases; 4. Normal liver function, kidney function, HIV/HCV, and electrocardiogram; 5. Meeting the diagnostic criteria for polycystic ovary syndrome (PCOS diagnostic criteria are based on the Rotterdam criteria in 2003), and excluding other diseases such as congenital adrenal hyperplasia, Cushing's syndrome, and androgen-secreting tumors; 6. Voluntarily participating in the trial after fully understanding the trial content and signing the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients diagnosed with diabetes (type 1 or type 2) before enrollment; 2. Patients with previous chronic diseases of the heart, liver, and kidneys; 3. Patients with a family history and personal history of thyroid cancer; 4. Patients with a history of drug allergy, allergic disorders or allergic constitution; smokers and heavy drinkers; 5. Patients with Cushing's syndrome, congenital adrenal hyperplasia, benign and malignant tumors of various systems, abnormal liver and kidney functions, organic heart diseases, rheumatoid arthritis, systemic lupus erythematosus, polycystic kidney, mental diseases, chronic diseases such as HIV/tuberculosis/HCV, etc.; 6. Patients with a history of using glucocorticoids, estrogens, progestogens, and insulin drugs within 3 months before enrollment; Patients who cannot cooperate with the follow-up for personal reasons; 7. Pregnant patients; 8. Also includes: 1) Patients who have participated in other clinical trials within one month before the test or are currently participating in other clinical trials; 2) Patients who the researchers consider not suitable for the clinical trial for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BMI;Waist-to-hip ratio;blood pressure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pregnancy status after follow - up medication; | — |
Countries
China
Contacts
Public ContactDongfang Liu/Cong Wang
The Second Affiliated Hospital of Chongqing Medical University
Outcome results
None listed